Free Republic

Hydroxychloroquine+azithromycin has been widely misrepresented in both clinical reports and public media, and outpatient trials results are not expected until September. Early outpatient illness is very different than later hospitalized florid disease and the treatments differ. Evidence about use of hydroxychloroquine alone, or of hydroxychloroquine+azithromycin in inpatients, is irrelevant concerning efficacy of the pair in early high-risk outpatient disease. Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multicomorbidities, with estimated proportion diagnosed with cardiac arrhythmias attributable to the medications 47/100,000...

The antimalarial drug hydroxychloroquine has shown mixed results against the coronavirus in early studies, but a new paper out of New York suggests combining it with the dietary supplement zinc sulfate could create a more effective treatment. The research by the NYU Grossman School of Medicine was posted on a medical preprint site on Monday, meaning it hasn't yet been peer reviewed. Records of about 900 COVID-19 patients were reviewed in the analysis, with roughly half given zinc sulfate along with hydroxychloroquine and the antibiotic azithromycin. The other half only received hydroxychloroquine and azithromycin. Those receiving the triple-drug combination had...